Journal
NEUROLOGY
Volume 77, Issue 19, Pages 1752-1755Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318236f0fd
Keywords
-
Categories
Funding
- American Academy of Neurology
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc
- National Ataxia Foundation
- Friedreich's Ataxia Research Association
- Bobby Allison Ataxia Research Center
- Movement Disorders Society
- GlaxoSmithKline
- Phytopharm
- Janssen (OrthoMcNeil)
- NIH/NINDS
- Spastic Paralysis Research Foundation of Kiwanis International
- Parkinson's Disease Foundation
- Takeda Pharmaceutical Company Limited
- ACADIA Pharmaceuticals
- Ipsen
- IMPAX Laboratories, Inc.
- XenoPort, Inc.
- Bayer Schering Pharma
- Allergan, Inc.
- Boehringer Ingelheim
- Allergan Inc.
- Medtronic, Inc.
- publication of Ultimate Neurology Review (DEMOS)
- Parkinson's Disease (Manson)
- Deep Brain Stimulation for Neurological and Psychiatric Diseases (Humana Press)
- NIH
- University of Florida Foundation
- Parkinson Alliance
- Michael J. Fox Foundation
- National Parkinson Foundation
- publication of Neurology for the Non-Neurologist
- Santhera Pharmaceuticals
Ask authors/readers for more resources
Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U). Neurology (R) 2011;77:1752-1755
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available